Navigation Links
Allos Therapeutics Reports Third Quarter 2007 Financial Results
Date:11/5/2007

of 150 to 325 mg/m2 of PDX. The maximum tolerated dose (MTD) was determined to be 270 mg/m2, which is nearly twice that observed in a previous Phase 1 study in which PDX was administered without vitamin supplementation. Clinically significant radiologic responses were observed. Greater than 50% of patients (13/22) received 2 or more prior treatment regimens. Based on PDX clinical experience to date, the Company plans to initiate a randomized Phase 2 study of PDX in patients with NSCLC.

PDX in NHL (Phase 1/2)

In October 2007, additional interim data from the Company's on-going Phase 1/2 study of PDX in patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease were presented at the 2007 AACR-NCI-EORTC conference. Responses were observed in 14 of 26 (54%) evaluable patients with T-cell lymphoma, with the duration of response typically exceeding the previously administered line of chemotherapy. No major safety concerns were identified in this heavily pre-treated population. These results are consistent with the interim data presented at the 2006 American Society of Hematology (ASH) meeting.

PDX In Vivo and In Vitro

In October 2007, results from a Company-sponsored pre-clinical study that investigated the mechanism of action of PDX and its differences from other antifolates, and compared the in vivo activity of PDX, methotrexate (MTX) and Alimta(R) against two NSCLC models were presented at the 2007 AACR-NCI-EORTC conference. The results suggest that PDX is mechanistically different from MTX and Alimta and that these differences may be due to enhanced uptake of PDX into the tumor cell and/or greater intracellular accumulation and polyglutamylation, resulting in greater inhibition of dihydrofolate reductase (DHFR). In addition, PDX induced greater tumor regression compared to MTX or Alimta in two human NSCLC xenograft models, including the highly aggressive H460 model.

RH1

RH1 is a novel small molecule chemotherapeutic agent that
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... Businesses Encouraged to Reduce Air Pollution, HARRISBURG, ... and its regional air quality partnerships have,forecast an ... in the,Berks/Lehigh, Liberty/Clairton, Philadelphia, Pittsburgh and Susquehanna,Valley regions., ... be code ORANGE for,ozone in the Berks/Lehigh Valley, ...
... brain are lost through disease or injury, neighboring cells begin ... the brain are able to produce new neurons. Patients with ... an area of the brain called the substantia nigra and ... these areas have not been well described because of limitations ...
... family reunion in Arkansas. The nurse and the research coordinator at The ... going West in search of the serum that binds this family. More ... ... Christine Demers and Areeba Sadiq set off for a family reunion in ...
... Program Encourages Kids to ,Eat Smart for a Great Start, ... ... ,Produce for Kids(R) (PFK), an organization that promotes the benefits of,healthy eating ... and tools that support the positive,development of the whole child - the ...
... N.J., Sept. 3 Teva,Pharmaceutical Industries Ltd. (Nasdaq: ... BRL ) announced today that, as expected, each ... referred to as a "second,request") from the U.S. ... acquisition of Barr. The parties have been cooperating ...
... 3 Z Trim Holdings,Inc. (Amex: ZTM ) issued ... September 3, 2008, To: Z Trim Shareholders, ... In this second installment of periodic updates intended to ... on the motives and,outcomes -- realized and anticipated -- behind ...
Cached Medicine News:Health News:Air Quality Action Day Forecast Thursday in All Regions 2Health News:New methods identify and manipulate 'newborn' cells in animal model of Parkinson's disease 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 3Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 4Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 2Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 3Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 4Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 6Health News:Teva and Barr Receive FTC Request for Additional Information 2Health News:Teva and Barr Receive FTC Request for Additional Information 3Health News:Teva and Barr Receive FTC Request for Additional Information 4Health News:Teva and Barr Receive FTC Request for Additional Information 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 2Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 3Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 4Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 6
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: